A	O
cross	O
-	O
sectional	O
study	O
to	O
estimate	O
high	O
-	O
risk	O
human	B-OG
papillomavirus	I-OG
prevalence	O
and	O
type	O
distribution	O
in	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O

Background	O

Pre	O
-	O
vaccination	O
information	O
on	O
HPV	B-OG
type	O
-	O
specific	O
prevalence	O
in	O
target	O
populations	O
is	O
essential	O
for	O
designing	O
and	O
monitoring	O
immunization	O
strategies	O
for	O
cervical	B-DS
cancer	I-DS
(	O
CC	B-DS
)	O
prevention	O
.	O

Data	O
on	O
HPV	B-OG
prevalence	O
in	O
Italy	O
are	O
available	O
for	O
women	O
over	O
the	O
age	O
of	O
24	O
years	O
,	O
target	O
of	O
the	O
population	O
-	O
based	O
CC	B-DS
screening	O
programmes	O
;	O
while	O
data	O
of	O
HPV	B-OG
prevalence	O
in	O
younger	O
ages	O
are	O
very	O
limited	O
.	O

The	O
present	O
study	O
enrolled	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O
in	O
order	O
to	O
assess	O
the	O
prevalence	O
and	O
distribution	O
of	O
high	O
-	O
risk	O
(	O
HR	O
)	O
HPV	B-OG
types	O
.	O

Risk	O
-	O
factors	O
correlated	O
with	O
HR	O
-	O
HPV	B-OG
positivity	O
were	O
also	O
described	O
.	O

Methods	O

A	O
sample	O
of	O
2	O
,	O
289	O
women	O
was	O
randomly	O
selected	O
from	O
the	O
resident	O
population	O
lists	O
of	O
ten	O
Local	O
Health	O
Units	O
(	O
LHUs	O
)	O
located	O
in	O
six	O
Italian	O
Regions	O
scattered	O
across	O
the	O
country	O
;	O
both	O
rural	O
and	O
urban	O
LHUs	O
were	O
involved	O
.	O

Women	O
aged	O
between	O
18	O
and	O
26	O
years	O
and	O
living	O
in	O
the	O
selected	O
LHUs	O
were	O
included	O
in	O
the	O
study	O
;	O
pregnant	O
women	O
and	O
women	O
who	O
did	O
not	O
speak	O
Italian	O
were	O
excluded	O
.	O

A	O
total	O
of	O
1	O
,	O
102	O
women	O
met	O
the	O
inclusion	O
criteria	O
and	O
agreed	O
to	O
participate	O
.	O

Participants	O
were	O
offered	O
pap	O
test	O
and	O
Hybrid	O
-	O
Capture	O
2	O
(	O
HC2	O
)	O
test	O
for	O
HR	O
-	O
HPV	B-OG
types	O
and	O
genotyping	O
was	O
performed	O
on	O
positive	O
smears	O
.	O

Results	O

Out	O
of	O
1	O
,	O
094	O
valid	O
samples	O
,	O
205	O
(	O
18	O
.	O
7	O
%)	O
were	O
HR	O
-	O
HPV	B-OG
positive	O
.	O

Women	O
with	O
2	O
–	O
4	O
(	O
ORadj	O
=	O
4	O
.	O
15	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
56	O
-	O
6	O
.	O
72	O
)	O
and	O
≥	O
5	O
lifetime	O
partners	O
(	O
ORadj	O
=	O
10	O
.	O
63	O
,	O
95	O
%	O
CI	O
:	O
6	O
.	O
16	O
-	O
18	O
.	O
36	O
)	O
and	O
women	O
who	O
have	O
used	O
any	O
contraceptive	O
in	O
the	O
last	O
six	O
months	O
(	O
ORadj	O
=	O
1	O
.	O
67	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
2	O
.	O
54	O
)	O
had	O
a	O
higher	O
risk	O
to	O
be	O
infected	O
;	O
women	O
living	O
with	O
their	O
partner	O
had	O
a	O
lower	O
risk	O
(	O
ORadj	O
=	O
0	O
.	O
56	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
34	O
-	O
0	O
.	O
92	O
)	O
to	O
acquire	O
infection	B-DS
than	O
women	O
living	O
with	O
parents	O
/	O
friends	O
/	O
alone	O
.	O

Among	O
HC2	O
positive	O
women	O
,	O
HPV16	B-OG
was	O
the	O
most	O
prevalent	O
type	O
(	O
30	O
.	O
9	O
%),	O
followed	O
by	O
31	O
(	O
19	O
.	O
6	O
%),	O
66	O
(	O
12	O
.	O
9	O
%),	O
51	O
(	O
11	O
.	O
3	O
%),	O
18	O
(	O
8	O
.	O
8	O
%),	O
56	O
(	O
8	O
.	O
8	O
%).	O

Co	B-DS
-	I-DS
infections	I-DS
of	O
HR	O
-	O
HC2	O
targeted	O
types	O
were	O
found	O
in	O
20	O
.	O
4	O
%	O
of	O
positive	O
samples	O
.	O

The	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
women	O
with	O
abnormal	O
cytology	O
(	O
52	O
.	O
4	O
%)	O
was	O
significantly	O
higher	O
than	O
in	O
women	O
with	O
normal	O
cytology	O
(	O
14	O
.	O
6	O
%);	O
however	O
33	O
.	O
0	O
%	O
of	O
HR	O
-	O
HPV	B-OG
infected	O
women	O
had	O
an	O
abnormal	O
cytology	O
.	O

Conclusion	O

HR	O
-	O
HPV	B-OG
prevalence	O
in	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O
was	O
19	O
%,	O
higher	O
than	O
what	O
detected	O
for	O
older	O
women	O
,	O
by	O
other	O
studies	O
using	O
the	O
same	O
molecular	O
method	O
and	O
laboratory	O
network	O
;	O
this	O
result	O
supports	O
the	O
choice	O
of	O
electing	O
girls	O
before	O
the	O
sexual	O
debut	O
as	O
the	O
primary	O
target	O
of	O
HPV	B-OG
vaccination	O
.	O

The	O
HPV	B-OG
type	O
distribution	O
found	O
in	O
this	O
study	O
may	O
represent	O
a	O
baseline	O
picture	O
;	O
an	O
accurate	O
post	O
-	O
vaccine	O
surveillance	O
is	O
necessary	O
to	O
early	O
detect	O
a	O
possible	O
genotype	O
replacement	O
.	O

The	O
high	O
prevalence	O
of	O
viral	O
types	O
other	O
than	O
vaccine	O
-	O
HPV	B-OG
types	O
supports	O
the	O
necessity	O
to	O
guarantee	O
the	O
progression	O
of	O
CC	B-DS
screening	O
programmes	O
in	O
vaccinated	O
women	O
.	O

Background	O

In	O
the	O
last	O
decade	O
many	O
studies	O
have	O
shown	O
that	O
infection	B-DS
with	O
high	O
-	O
risk	O
(	O
HR	O
)	O
types	O
of	O
human	B-OG
papillomavirus	I-OG
(	O
HPV	B-OG
)	O
is	O
a	O
necessary	O
condition	O
for	O
the	O
development	O
of	O
invasive	O
cervical	B-DS
cancer	I-DS
(	O
CC	B-DS
)	O
[	O
1	O
].	O

Genital	O
HPV	B-DS
infection	I-DS
is	O
very	O
common	O
in	O
sexually	O
active	O
women	O
and	O
is	O
transient	O
in	O
most	O
cases	O
;	O
only	O
women	O
with	O
persistent	B-DS
infection	I-DS
by	O
HR	O
-	O
HPV	B-OG
types	O
are	O
likely	O
to	O
develop	O
a	O
cervical	B-DS
lesion	I-DS
[	O
2	O
].	O

These	O
findings	O
led	O
to	O
the	O
development	O
of	O
prophylactic	O
vaccines	O
targeted	O
to	O
provide	O
protection	O
against	O
HPV16	B-OG
and	O
18	O
,	O
responsible	O
for	O
the	O
70	O
%	O
of	O
all	O
cervical	B-DS
cancers	I-DS
;	O
efficacy	O
has	O
been	O
shown	O
to	O
be	O
highest	O
in	O
subjects	O
naïf	O
to	O
the	O
infection	B-DS
[	O
3	O
,	O
4	O
].	O

As	O
of	O
July	O
2010	O
,	O
18	O
European	O
countries	O
had	O
integrated	O
HPV	B-OG
vaccination	O
in	O
their	O
national	O
immunization	O
programmes	O
,	O
most	O
of	O
them	O
targeting	O
pre	O
-	O
adolescent	O
girls	O
;	O
nine	O
countries	O
had	O
also	O
planned	O
catch	O
up	O
programmes	O
for	O
older	O
girls	O
[	O
5	O
].	O

In	O
Italy	O
HPV	B-OG
vaccination	O
is	O
included	O
in	O
the	O
national	O
immunization	O
program	O
and	O
is	O
offered	O
to	O
11	O
year	O
-	O
old	O
girls	O
since	O
2007	O
[	O
6	O
];	O
six	O
of	O
the	O
21	O
Italian	O
Regions	O
have	O
also	O
extended	O
the	O
offer	O
to	O
one	O
older	O
birth	O
cohort	O
(	O
varying	O
by	O
Region	O
between	O
15	O
–	O
18	O
years	O
),	O
and	O
one	O
Region	O
to	O
three	O
cohorts	O
(	O
15	O
,	O
18	O
and	O
24	O
year	O
-	O
old	O
)	O
[	O
7	O
].	O

Pre	O
-	O
vaccination	O
distribution	O
of	O
HPV	B-OG
genotypes	O
in	O
target	O
populations	O
is	O
essential	O
for	O
designing	O
,	O
monitoring	O
and	O
evaluating	O
immunization	O
strategies	O
.	O

Baseline	O
prevalence	O
is	O
relevant	O
to	O
estimate	O
vaccine	O
effectiveness	O
against	O
the	O
HPV	B-OG
-	O
vaccine	O
types	O
,	O
to	O
evaluate	O
the	O
cross	O
-	O
protection	O
of	O
the	O
vaccines	O
,	O
and	O
to	O
monitor	O
over	O
time	O
the	O
relative	O
frequency	O
of	O
genotypes	O
under	O
the	O
selective	O
pressure	O
of	O
the	O
vaccines	O
.	O

Data	O
on	O
HPV	B-OG
prevalence	O
in	O
Italy	O
are	O
available	O
for	O
women	O
over	O
the	O
age	O
of	O
24	O
years	O
[	O
8	O
-	O
10	O
],	O
target	O
of	O
the	O
population	O
-	O
based	O
CC	B-DS
screening	O
programmes	O
.	O

On	O
the	O
contrary	O
there	O
is	O
very	O
limited	O
amount	O
of	O
data	O
on	O
HPV	B-OG
prevalence	O
in	O
younger	O
ages	O
[	O
11	O
,	O
12	O
].	O

The	O
present	O
study	O
enrolled	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O
in	O
order	O
to	O
assess	O
the	O
prevalence	O
of	O
HR	O
-	O
HPV	B-OG
types	O
and	O
detect	O
the	O
prevalent	O
genotypes	O
.	O

Risk	O
-	O
factors	O
correlated	O
with	O
HR	O
-	O
HPV	B-OG
positivity	O
were	O
also	O
described	O
.	O

Methods	O

Study	O
design	O
and	O
study	O
population	O

This	O
cross	O
-	O
sectional	O
study	O
was	O
carried	O
out	O
in	O
the	O
period	O
2007	O
–	O
2009	O
,	O
coordinated	O
by	O
the	O
Istituto	O
Superiore	O
di	O
Sanità	O
(	O
ISS	O
,	O
Italy	O
’	O
s	O
National	O
Institute	O
of	O
Public	O
Health	O
)	O
and	O
partially	O
sponsored	O
by	O
the	O
Ministry	O
of	O
Health	O
.	O

It	O
was	O
part	O
of	O
a	O
national	O
project	O
(	O
PreGio	O
),	O
which	O
also	O
included	O
a	O
KAP	O
(	O
knowledge	O
-	O
attitudes	O
-	O
practices	O
)	O
survey	O
on	O
HPV	B-DS
infection	I-DS
and	O
CC	B-DS
prevention	O
[	O
13	O
]	O
and	O
a	O
study	O
to	O
estimate	O
the	O
acceptance	O
rate	O
of	O
HPV	B-OG
vaccination	O
[	O
14	O
]	O
.	O

A	O
sample	O
of	O
2	O
,	O
289	O
women	O
was	O
randomly	O
selected	O
from	O
the	O
resident	O
population	O
lists	O
of	O
ten	O
Local	O
Health	O
Units	O
(	O
LHU	O
)	O
located	O
in	O
six	O
Italian	O
Regions	O
scattered	O
across	O
the	O
country	O
:	O
Abruzzo	O
and	O
Campania	O
in	O
southern	O
Italy	O
(	O
1	O
,	O
026	O
),	O
Lazio	O
and	O
Tuscany	O
in	O
central	O
Italy	O
(	O
388	O
)	O
and	O
Emilia	O
-	O
Romagna	O
and	O
Piedmont	O
in	O
northern	O
Italy	O
(	O
875	O
).	O

Both	O
rural	O
and	O
urban	O
LHUs	O
were	O
involved	O
;	O
all	O
10	O
LHUs	O
have	O
population	O
-	O
based	O
CC	B-DS
screening	O
programmes	O
.	O

The	O
inclusion	O
criteria	O
for	O
the	O
study	O
were	O
:	O
women	O
aged	O
between	O
18	O
and	O
26	O
years	O
and	O
living	O
in	O
the	O
selected	O
LHUs	O
.	O

Pregnant	O
women	O
and	O
women	O
who	O
did	O
not	O
speak	O
Italian	O
were	O
excluded	O
.	O

The	O
women	O
were	O
stratified	O
into	O
two	O
age	O
groups	O
(	O
18	O
–	O
24	O
and	O
25	O
–	O
26	O
years	O
),	O
partially	O
overlapping	O
(	O
25	O
–	O
26	O
years	O
)	O
with	O
the	O
target	O
age	O
of	O
population	O
-	O
based	O
CC	B-DS
screening	O
.	O

Procedures	O
for	O
enrolling	O
participants	O
as	O
well	O
as	O
study	O
methodology	O
have	O
already	O
been	O
described	O
[	O
13	O
,	O
14	O
].	O

All	O
women	O
were	O
offered	O
Pap	O
-	O
test	O
and	O
HPV	B-OG
test	O
;	O
a	O
written	O
informed	O
consent	O
was	O
obtained	O
by	O
each	O
participant	O
.	O

Selected	O
midwives	O
,	O
especially	O
trained	O
for	O
this	O
study	O
,	O
were	O
in	O
charge	O
of	O
contacting	O
sampled	O
women	O
,	O
collecting	O
socio	O
-	O
demographic	O
data	O
and	O
information	O
regarding	O
sexual	O
and	O
reproductive	O
history	O
,	O
getting	O
informed	O
consent	O
and	O
performing	O
cervical	O
smears	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
national	O
ethics	O
committee	O
of	O
the	O
ISS	O
.	O

Cytology	O

Cervical	O
smears	O
were	O
taken	O
according	O
to	O
the	O
consolidate	O
CC	B-DS
-	O
screening	O
procedures	O
at	O
the	O
LHU	O
.	O

In	O
most	O
Regions	O
(	O
Tuscany	O
,	O
Piedmont	O
,	O
Emilia	O
-	O
Romagna	O
,	O
Lazio	O
,	O
Campania	O
)	O
two	O
cervical	O
samples	O
were	O
taken	O
:	O
one	O
for	O
Pap	O
-	O
test	O
and	O
one	O
for	O
the	O
HPV	B-OG
test	O
in	O
Specimen	O
Transport	O
Medium	O
(	O
STM	O
,	O
DNAPAP	O
cervical	O
sampler	O
,	O
Qiagen	O
,	O
Gaithersburg	O
,	O
USA	O
);	O
for	O
STM	O
sample	O
,	O
cytobrush	O
was	O
used	O
to	O
obtain	O
samples	O
.	O

In	O
Abruzzo	O
Region	O
the	O
cervical	O
cell	O
specimens	O
were	O
put	O
in	O
PreservCyt	O
solution	O
(	O
Hologic	O
,	O
Inc	O
.,	O
Marlborough	O
,	O
MA	O
)	O
and	O
used	O
both	O
for	O
HPV	B-OG
testing	O
and	O
for	O
cytological	O
examination	O
;	O
for	O
Preservcyt	O
sample	O
,	O
Ayre	O
spatula	O
and	O
cytobrush	O
were	O
used	O
.	O

The	O
cytology	O
was	O
interpreted	O
locally	O
according	O
to	O
Bethesda	O
2001	O
system	O
[	O
15	O
].	O

Information	O
on	O
reproductive	O
,	O
sexual	O
and	O
cervical	O
screening	O
history	O
were	O
collected	O
(	O
Table	O
1	O
).	O

Characteristics	O
of	O
the	O
study	O
population	O

Characteristics	O


n	O
(%)	O

N	O

Socio	O
-	O
demographic	O
characteristics	O

Mean	O
age	O
(	O
years	O
)	O


23	O
.	O
8	O
±	O
0	O
.	O
07	O
*	O

1	O
,	O
094	O

Age	O
group	O

18	O
–	O
24	O
years	O

598	O
(	O
54	O
.	O
7	O
)	O

1	O
,	O
094	O


25	O
–	O
26	O
years	O

496	O
(	O
45	O
.	O
3	O
)	O


Geographical	O
area	O
of	O
residence	O

North	O

445	O
(	O
40	O
.	O
7	O
)	O

1	O
,	O
094	O


Centre	O

235	O
(	O
21	O
.	O
5	O
)	O



South	O

414	O
(	O
37	O
.	O
8	O
)	O


Nationality	O

Foreign	O

69	O
(	O
6	O
.	O
3	O
)	O

1	O
,	O
092	O


Italian	O

1	O
,	O
023	O
(	O
93	O
.	O
7	O
)	O


Educational	O
level	O

Low	O
(≤	O
8	O
years	O
)	O

216	O
(	O
19	O
.	O
8	O
)	O

1	O
,	O
090	O


High	O
(>	O
8	O
years	O
)	O

874	O
(	O
80	O
.	O
2	O
)	O


Employment	O
status	O

Student	O

455	O
(	O
42	O
.	O
0	O
)	O

1	O
,	O
084	O


Employed	O

415	O
(	O
38	O
.	O
3	O
)	O



Unemployed	O

163	O
(	O
15	O
.	O
0	O
)	O



Housewife	O

51	O
(	O
4	O
.	O
7	O
)	O


Marital	O
status	O

Single	O

974	O
(	O
89	O
.	O
3	O
)	O

1	O
,	O
091	O


Married	O

113	O
(	O
10	O
.	O
3	O
)	O



Divorced	O

4	O
(	O
0	O
.	O
4	O
)	O


Lives	O
with	O

parents	O

813	O
(	O
74	O
.	O
7	O
)	O

1	O
,	O
089	O


partner	O

185	O
(	O
17	O
.	O
0	O
)	O



alone	O

48	O
(	O
4	O
.	O
4	O
)	O



friends	O

43	O
(	O
3	O
.	O
9	O
)	O


Sexual	O
behaviour	O
and	O
reproductive	O
history	O

Mean	O
age	O
at	O
first	O
sexual	O
intercourse	O
(	O
years	O
)	O


17	O
.	O
5	O
±	O
0	O
.	O
1	O
*	O

1	O
,	O
089	O

Parity	O

0	O

988	O
(	O
90	O
.	O
4	O
)	O

1	O
,	O
093	O


≥	O
1child	O

105	O
(	O
9	O
.	O
6	O
)	O


Mean	O
age	O
at	O
first	O
delivery	O
(	O
years	O
)	O


21	O
.	O
7	O
±	O
0	O
.	O
3	O
*	O

105	O

No	O
.	O
of	O
lifetime	O
partners	O

1	O

377	O
(	O
34	O
.	O
6	O
)	O

1	O
,	O
091	O


2	O
–	O
4	O

558	O
(	O
51	O
.	O
1	O
)	O



≥	O
5	O

156	O
(	O
14	O
.	O
3	O
)	O


No	O
.	O
of	O
partners	O
in	O
the	O
last	O
6	O
months	O

0	O

69	O
(	O
6	O
.	O
3	O
)	O

1	O
,	O
093	O


1	O

962	O
(	O
88	O
.	O
0	O
)	O



2	O
–	O
4	O

53	O
(	O
4	O
.	O
9	O
)	O



≥	O
5	O

9	O
(	O
0	O
.	O
8	O
)	O


Use	O
of	O
contraceptives	O
in	O
the	O
last	O
6	O
months	O

Yes	O

762	O
(	O
74	O
.	O
5	O
)	O

1	O
,	O
023	O


No	O

261	O
(	O
25	O
.	O
5	O
)	O


Use	O
of	O
condoms	O
in	O
the	O
last	O
6	O
months	O

Always	O

346	O
(	O
33	O
.	O
9	O
)	O

1	O
,	O
020	O


Rarely	O

307	O
(	O
30	O
.	O
1	O
)	O



Never	O

369	O
(	O
36	O
.	O
0	O
)	O


Previous	O
Pap	O
-	O
test	O

Yes	O

420	O
(	O
38	O
.	O
5	O
)	O

1	O
,	O
091	O


No	O

671	O
(	O
61	O
.	O
5	O
)	O


*	O
(	O
mean	O
±	O
Standard	O
Error	O
).	O

Women	O
aged	O
25	O
–	O
26	O
years	O
followed	O
the	O
routine	O
protocol	O
of	O
treatment	O
or	O
follow	O
-	O
up	O
according	O
to	O
cytological	O
results	O
.	O

A	O
specific	O
protocol	O
for	O
18	O
–	O
24	O
year	O
-	O
old	O
women	O
was	O
adopted	O
:	O
colposcopy	O
was	O
offered	O
to	O
women	O
with	O
HSIL	O
(	O
high	O
squamous	B-DS
intraepithelial	I-DS
lesions	I-DS
)	O
and	O
ASCH	O
(	O
atypical	O
squamous	O
cells	O
that	O
cannot	O
exclude	O
high	O
-	O
grade	O
lesions	B-DS
),	O
while	O
women	O
with	O
LSIL	O
(	O
low	O
squamous	B-DS
intraepithelial	I-DS
lesions	I-DS
)	O
or	O
less	O
severe	O
lesions	B-DS
were	O
invited	O
to	O
repeat	O
pap	O
-	O
test	O
two	O
years	O
later	O
and	O
colposcopy	O
was	O
offered	O
only	O
if	O
,	O
after	O
two	O
years	O
,	O
the	O
diagnosis	O
was	O
still	O
LSIL	O
or	O
it	O
progressed	O
to	O
a	O
more	O
severe	O
lesion	B-DS
.	O

HPV	B-OG
testing	O

The	O
HPV	B-OG
test	O
was	O
performed	O
using	O
Hybrid	O
Capture	O
2	O
(	O
HC2	O
High	O
-	O
Risk	O
HPV	B-OG
DNA	O
,	O
Qiagen	O
;	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

It	O
is	O
a	O
hybridization	O
assay	O
which	O
detects	O
the	O
presence	O
of	O
HPV	B-OG
-	O
DNA	O
using	O
cocktails	O
of	O
RNA	O
probes	O
and	O
an	O
amplified	O
,	O
chemiluminescent	O
signal	O
.	O

The	O
high	O
-	O
risk	O
group	O
of	O
probes	O
B	O
,	O
designed	O
to	O
detect	O
HPV	B-OG
types	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
and	O
68	O
,	O
was	O
used	O
.	O

The	O
assay	O
is	O
calibrated	O
on	O
a	O
positive	O
cut	O
off	O
(	O
pc	O
)	O
of	O
1	O
pg	O
/	O
ml	O
of	O
HPV	B-OG
-	O
DNA	O
.	O

Samples	O
were	O
considered	O
positive	O
when	O
the	O
ratio	O
between	O
the	O
Relative	O
Light	O
Units	O
(	O
RLU	O
)	O
of	O
specimen	O
and	O
the	O
pc	O
attained	O
or	O
exceeded	O
the	O
value	O
of	O
1	O
.	O
0	O
.	O

A	O
regional	O
laboratory	O
was	O
identified	O
in	O
Tuscany	O
,	O
Piedmont	O
,	O
Abruzzo	O
and	O
Emilia	O
-	O
Romagna	O
Regions	O
for	O
performing	O
HPV	B-OG
testing	O
;	O
the	O
Analytical	O
and	O
Biomolecular	O
Cytology	O
Unit	O
of	O
the	O
Cancer	O
Prevention	O
and	O
Research	O
Institute	O
(	O
ISPO	O
)	O
in	O
Tuscany	O
also	O
analysed	O
samples	O
from	O
Campania	O
and	O
Lazio	O
Regions	O
.	O

Genotyping	O

Genotyping	O
was	O
performed	O
on	O
HR	O
-	O
HC2	O
positive	O
samples	O
.	O

DNA	O
was	O
extracted	O
using	O
the	O
QIAamp	O
DNAMini	O
kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

For	O
PreservCyt	O
™	O
samples	O
the	O
elution	O
volume	O
varied	O
from	O
80	O
to	O
100	O
μl	O
depending	O
on	O
the	O
size	O
of	O
the	O
pellet	O
,	O
while	O
for	O
STM	O
samples	O
100	O
μl	O
of	O
elution	O
buffer	O
(	O
Buffer	O
AE	O
)	O
were	O
used	O
.	O

To	O
facilitate	O
a	O
higher	O
recovery	O
of	O
DNA	O
a	O
double	O
elution	O
was	O
done	O
for	O
all	O
the	O
samples	O
.	O

HR	O
-	O
HC2	O
positive	O
samples	O
were	O
typed	O
using	O
the	O
“	O
Consensus	O
High	O
Risk	O
HPV	B-OG
genotyping	O
”	O
kit	O
assay	O
(	O
Digene	O
Corporation	O
,	O
Gaithersburg	O
,	O
USA	O
).	O

The	O
test	O
is	O
based	O
on	O
the	O
reverse	O
hybridization	O
principle	O
.	O

Denaturated	O
biotynilated	O
amplicons	O
,	O
resulting	O
from	O
the	O
amplification	O
of	O
a	O
part	O
of	O
the	O
L1	O
region	O
with	O
GP5	B-GP
+/	O
GP6	B-GP
+	O
primers	O
,	O
were	O
hybridized	O
with	O
specific	O
oligonucleotide	O
probes	O
,	O
which	O
were	O
immobilized	O
as	O
parallel	O
lines	O
on	O
membrane	O
strips	O
(	O
Reverse	O
Line	O
Blot	O
Hybridization	O
).	O

The	O
hybrids	O
were	O
detected	O
with	O
alkaline	B-GP
phosphatase	I-GP
–	O
streptavidin	B-GP
conjugate	O
and	O
substrate	O
(	O
5	O
-	O
bromo	O
-	O
4	O
-	O
chloro	O
-	O
3	O
-	O
indolylphosphate	O
and	O
nitroblue	O
tetrazolium	O
),	O
resulting	O
in	O
a	O
purple	O
precipitate	O
at	O
positive	O
probe	O
lines	O
.	O

The	O
kit	O
allows	O
the	O
identification	O
of	O
18	O
HPV	B-OG
types	O
(	O
16	O
,	O
18	O
,	O
26	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
66	O
,	O
68	O
,	O
73	O
,	O
82	O
).	O

One	O
HPV	B-OG
-	O
positive	O
control	O
and	O
two	O
negative	O
PCR	O
controls	O
(	O
a	O
purified	O
DNA	O
sample	O
negative	O
for	O
HPV	B-OG
and	O
a	O
DNA	O
free	O
sample	O
)	O
were	O
included	O
in	O
each	O
PCR	O
run	O
and	O
subsequent	O
Reverse	O
Line	O
Blot	O
(	O
RLB	O
).	O

GP5	B-GP
+/	O
GP6	B-GP
+	O
PCR	O
-	O
negative	O
and	O
RLB	O
-	O
negative	O
samples	O
were	O
amplified	O
for	O
the	O
β	B-GP
-	I-GP
globin	I-GP
gene	O
sequence	O
using	O
GH20	O
-	O
PC04	O
primers	O
(	O
268	O
-	O
bp	O
amplicon	O
length	O
)	O
to	O
assess	O
DNA	O
integrity	O
(	O
Bauer	O
).	O

The	O
molecular	O
Laboratory	O
of	O
ISPO	O
performed	O
genotyping	O
of	O
samples	O
collected	O
in	O
all	O
Italian	O
regions	O
involved	O
in	O
the	O
study	O
except	O
samples	O
collected	O
in	O
Piedmont	O
Region	O
,	O
which	O
were	O
genotyped	O
at	O
the	O
Center	O
for	O
Experimental	O
Research	O
and	O
Medical	O
Science	O
of	O
the	O
Turin	O
University	O
.	O

ISPO	O
also	O
coordinated	O
the	O
molecular	O
activities	O
of	O
the	O
whole	O
project	O
,	O
standardizing	O
the	O
procedures	O
for	O
storing	O
and	O
analysing	O
the	O
samples	O
according	O
to	O
a	O
protocol	O
defined	O
to	O
guarantee	O
the	O
quality	O
of	O
molecular	O
methods	O
[	O
16	O
].	O

Statistical	O
analysis	O

Categorical	O
variables	O
were	O
summarized	O
by	O
absolute	O
frequencies	O
and	O
percentages	O
,	O
and	O
continuous	O
variables	O
by	O
means	O
and	O
Standard	O
Error	O
(	O
SE	O
).	O

The	O
Chi	O
-	O
square	O
test	O
and	O
Fisher	O
’	O
s	O
exact	O
test	O
were	O
used	O
to	O
compare	O
proportions	O
;	O
the	O
t	O
-	O
test	O
or	O
Mann	O
–	O
Whitney	O
nonparametric	O
test	O
was	O
used	O
to	O
compare	O
continuous	O
variables	O
.	O

Crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
were	O
calculated	O
to	O
evaluate	O
the	O
association	O
between	O
the	O
HR	O
-	O
HPV	B-OG
positivity	O
and	O
socio	O
-	O
behavioural	O
characteristics	O
.	O

Confounding	O
was	O
assessed	O
by	O
a	O
multivariate	O
logistic	O
regression	O
approach	O
;	O
all	O
variables	O
with	O
a	O
p	O
-	O
value	O
≤	O
0	O
.	O
15	O
in	O
the	O
univariate	O
analysis	O
were	O
included	O
in	O
the	O
multivariate	O
model	O
and	O
retained	O
in	O
the	O
final	O
model	O
according	O
to	O
a	O
log	O
-	O
likelihood	O
-	O
ratio	O
test	O
for	O
goodness	O
-	O
of	O
-	O
fit	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
STATA	O
11	O
.	O
2	O
(	O
Stata	O
Corporation	O
,	O
College	O
Station	O
,	O
Texas	O
,	O
USA	O
).	O

Results	O

Study	O
population	O

Recruitment	O
was	O
performed	O
in	O
the	O
period	O
ranging	O
from	O
February	O
2008	O
to	O
April	O
2009	O
.	O

The	O
initial	O
sample	O
included	O
2	O
,	O
289	O
women	O
;	O
239	O
did	O
not	O
meet	O
the	O
inclusion	O
criteria	O
(	O
124	O
did	O
not	O
live	O
in	O
the	O
selected	O
LHU	O
,	O
57	O
were	O
pregnant	O
,	O
45	O
were	O
not	O
included	O
in	O
the	O
18	O
–	O
26	O
years	O
range	O
of	O
age	O
and	O
13	O
did	O
not	O
speak	O
Italian	O
)	O
and	O
were	O
replaced	O
,	O
and	O
290	O
could	O
not	O
be	O
contacted	O
.	O

Thus	O
1	O
,	O
999	O
women	O
were	O
offered	O
Pap	O
test	O
and	O
HPV	B-OG
test	O
.	O

Among	O
them	O
,	O
897	O
(	O
44	O
.	O
9	O
%)	O
declined	O
participation	O
for	O
several	O
issues	O
(	O
non	O
interested	O
in	O
the	O
study	O
,	O
practical	O
constraints	O
,	O
health	O
disorders	O
,	O
HPV	B-OG
-	O
positivity	O
,	O
recent	O
previous	O
Pap	O
-	O
test	O
,	O
embarrassment	O
,	O
parental	O
advice	O
,	O
safety	O
concerns	O
,	O
no	O
sexual	O
activity	O
)	O
(	O
Figure	O
1	O
).	O

Women	O
who	O
did	O
not	O
participate	O
were	O
slightly	O
younger	O
than	O
participants	O
(	O
mean	O
age	O
23	O
.	O
2	O
±	O
0	O
.	O
09	O
vs	O
.	O
23	O
.	O
9	O
±	O
0	O
.	O
07	O
years	O
;	O
p	O
<	O
0	O
.	O
001	O
);	O
the	O
proportion	O
of	O
women	O
with	O
a	O
lower	O
education	O
level	O
(	O
24	O
.	O
6	O
%	O
vs	O
19	O
.	O
9	O
%;	O
p	O
=	O
0	O
.	O
017	O
),	O
living	O
with	O
parents	O
(	O
87	O
.	O
9	O
vs	O
74	O
.	O
6	O
%;	O
p	O
=	O
0	O
<	O
001	O
),	O
unmarried	O
(	O
93	O
.	O
5	O
vs	O
89	O
.	O
5	O
%;	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
living	O
in	O
southern	O
Italy	O
(	O
53	O
.	O
3	O
%	O
vs	O
38	O
.	O
0	O
%;	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
higher	O
in	O
the	O
group	O
of	O
women	O
who	O
refused	O
to	O
participate	O
.	O

Study	O
population	O
.	O
*	O
Not	O
traced	O
:	O
women	O
who	O
were	O
not	O
traced	O
although	O
three	O
phone	O
calls	O
and	O
two	O
home	O
visits	O
.	O
**	O
Not	O
eligible	O
:	O
women	O
who	O
did	O
not	O
meet	O
inclusion	O
criteria	O
and	O
were	O
replaced	O
with	O
women	O
of	O
the	O
same	O
age	O
group	O
and	O
local	O
health	O
unit	O
.	O
***	O
Declined	O
participation	O
:	O
women	O
who	O
were	O
contacted	O
and	O
met	O
the	O
inclusion	O
criteria	O
,	O
but	O
refused	O
to	O
participate	O
in	O
the	O
prevalence	O
study	O
.	O
‡	O
Un	O
-	O
typeable	O
samples	O
:	O
HR	O
-	O
HC2	O
positive	O
samples	O
that	O
resulted	O
negative	O
at	O
any	O
of	O
the	O
18	O
types	O
identifiable	O
by	O
the	O
kit	O
assay	O
used	O
for	O
genotyping	O
.	O

In	O
conclusion	O
a	O
total	O
of	O
1	O
,	O
102	O
out	O
of	O
2	O
,	O
289	O
women	O
(	O
48	O
.	O
1	O
%)	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
order	O
to	O
calculate	O
the	O
participation	O
rate	O
to	O
the	O
prevalence	O
study	O
,	O
we	O
considered	O
more	O
appropriate	O
to	O
exclude	O
from	O
the	O
denominator	O
(	O
2	O
,	O
289	O
)	O
the	O
154	O
women	O
(	O
among	O
the	O
897	O
women	O
who	O
declined	O
participation	O
)	O
who	O
spontaneously	O
declared	O
not	O
to	O
be	O
sexually	O
active	O
:	O
therefore	O
the	O
participation	O
rate	O
was	O
51	O
.	O
6	O
%	O
(	O
1	O
,	O
102	O
/	O
2	O
,	O
135	O
),	O
with	O
a	O
range	O
among	O
LHUs	O
of	O
23	O
.	O
9	O
-	O
80	O
.	O
7	O
.	O

The	O
mean	O
age	O
of	O
participants	O
was	O
23	O
.	O
8	O
±	O
0	O
.	O
07	O
years	O
;	O
40	O
.	O
7	O
%	O
lived	O
in	O
northern	O
Italy	O
,	O
37	O
.	O
8	O
%	O
in	O
southern	O
Italy	O
,	O
and	O
21	O
.	O
5	O
%	O
in	O
central	O
Italy	O
.	O

Most	O
women	O
were	O
Italian	O
(	O
93	O
.	O
7	O
%),	O
unmarried	O
(	O
89	O
.	O
3	O
%)	O
and	O
had	O
a	O
high	O
educational	O
level	O
,	O
defined	O
as	O
>	O
8	O
years	O
of	O
education	O
(	O
80	O
.	O
2	O
%).	O

Detailed	O
socio	O
-	O
behavioural	O
characteristics	O
are	O
shown	O
in	O
Table	O
1	O
.	O

HPV	B-OG
prevalence	O
and	O
genotyping	O

The	O
Pap	O
-	O
test	O
was	O
performed	O
on	O
1	O
,	O
099	O
cervical	O
smears	O
because	O
three	O
samples	O
were	O
missed	O
(	O
they	O
were	O
included	O
in	O
the	O
CC	B-DS
screening	O
programme	O
,	O
instead	O
of	O
being	O
included	O
in	O
the	O
PreGio	O
study	O
)	O
and	O
the	O
HR	O
-	O
HPV	B-OG
testing	O
was	O
performed	O
on	O
1	O
,	O
094	O
out	O
of	O
1	O
,	O
999	O
samples	O
(	O
the	O
material	O
of	O
five	O
samples	O
was	O
not	O
sufficient	O
for	O
HR	O
-	O
HC2	O
test	O
).	O

The	O
proportion	O
of	O
HR	O
-	O
HC2	O
positive	O
samples	O
was	O
18	O
.	O
7	O
%	O
(	O
205	O
/	O
1	O
,	O
094	O
)	O
and	O
did	O
not	O
differ	O
by	O
geographic	O
area	O
and	O
age	O
group	O
(	O
Table	O
2	O
).	O

Determinants	O
of	O
HR	O
-	O
HPV	B-OG
prevalence	O
:	O
univariate	O
(	O
OR	O
crude	O
)	O
and	O
multivariate	O
(	O
OR	O
adj	O
)	O
logistic	O
regression	O
analysis	O

Characteristics	O

HR	O
-	O
HPV	B-OG
positivity	O

Univariate	O
analysis	O

Multivariate	O
model	O
**	O



n	O
/	O
N	O
(%)	O

OR	O
crude	O

95	O
%	O
CI	O

OR	O
adj	O

95	O
%	O
CI	O

Age	O
Group	O

18	O
-	O
24	O
years	O

119	O
/	O
597	O
(	O
19	O
.	O
9	O
)	O

1	O

-	O




25	O
-	O
26	O
years	O

86	O
/	O
496	O
(	O
17	O
.	O
3	O
)	O

0	O
.	O
84	O

(	O
0	O
.	O
62	O
–	O
1	O
.	O
14	O
)	O



Geographical	O
area	O
of	O
residence	O

Centre	O

44	O
/	O
235	O
(	O
18	O
.	O
8	O
)	O

1	O

-	O




North	O

86	O
/	O
445	O
(	O
19	O
.	O
3	O
)	O

1	O
.	O
03	O

(	O
0	O
.	O
69	O
–	O
1	O
.	O
55	O
)	O




South	O

75	O
/	O
414	O
(	O
18	O
.	O
1	O
)	O

0	O
.	O
95	O

(	O
0	O
.	O
63	O
–	O
1	O
.	O
44	O
)	O



Nationality	O

Foreign	O

13	O
/	O
69	O
(	O
18	O
.	O
8	O
)	O

1	O

-	O




Italian	O

192	O
/	O
1023	O
(	O
18	O
.	O
7	O
)	O

0	O
.	O
99	O

(	O
0	O
.	O
53	O
–	O
1	O
.	O
86	O
)	O



Educational	O
level	O

Low	O
(≤	O
8	O
years	O
)	O

39	O
/	O
216	O
(	O
18	O
.	O
1	O
)	O

1	O

-	O




High	O
(>	O
8	O
years	O
)	O

166	O
/	O
874	O
(	O
19	O
.	O
0	O
)	O

1	O
.	O
06	O

(	O
0	O
.	O
72	O
–	O
1	O
.	O
56	O
)	O



Employment	O
status	O

Student	O

79	O
/	O
455	O
(	O
17	O
.	O
4	O
)	O

1	O

-	O




Employed	O

80	O
/	O
415	O
(	O
19	O
.	O
3	O
)	O

1	O
.	O
14	O

(	O
0	O
.	O
80	O
–	O
1	O
.	O
60	O
)	O




Other	O

45	O
/	O
214	O
(	O
21	O
.	O
0	O
)	O

1	O
.	O
27	O

(	O
0	O
.	O
84	O
–	O
1	O
.	O
91	O
)	O



Marital	O
status	O

Single	O

197	O
/	O
974	O
(	O
20	O
.	O
2	O
)	O

1	O

-	O




Married	O

8	O
/	O
113	O
(	O
7	O
.	O
1	O
)	O

0	O
.	O
30	O

(	O
0	O
.	O
14	O
–	O
0	O
.	O
63	O
)	O



Lives	O
with	O

Parents	O
/	O
friends	O
/	O
alone	O

182	O
/	O
904	O
(	O
20	O
.	O
1	O
)	O

1	O

-	O

1	O

-	O


Partner	O

22	O
/	O
185	O
(	O
11	O
.	O
9	O
)	O

0	O
.	O
53	O

(	O
0	O
.	O
33	O
–	O
0	O
.	O
86	O
)	O

0	O
.	O
56	O

(	O
0	O
.	O
34	O
-	O
0	O
.	O
92	O
)	O

Mean	O
age	O
at	O
first	O
sexual	O
intercourse	O
(	O
years	O
)	O


*	O
17	O
.	O
2	O

0	O
.	O
92	O

(	O
0	O
.	O
85	O
–	O
0	O
.	O
99	O
)	O



Parity	O

0	O

195	O
/	O
988	O
(	O
19	O
.	O
7	O
)	O

1	O

-	O




≥	O
1	O
child	O

10	O
/	O
105	O
(	O
9	O
.	O
5	O
)	O

0	O
.	O
43	O

(	O
0	O
.	O
22	O
–	O
0	O
.	O
84	O
)	O



Mean	O
age	O
at	O
first	O
delivery	O
(	O
years	O
)	O


*	O
21	O
.	O
8	O

1	O
.	O
01	O

(	O
0	O
.	O
78	O
–	O
1	O
.	O
30	O
)	O



No	O
.	O
of	O
lifetime	O
partners	O

1	O

25	O
/	O
377	O
(	O
6	O
.	O
3	O
)	O

1	O

-	O

1	O

-	O


2	O
-	O
4	O

118	O
/	O
558	O
(	O
21	O
.	O
1	O
)	O

3	O
.	O
78	O

(	O
2	O
.	O
40	O
–	O
5	O
.	O
94	O
)	O

4	O
.	O
15	O

(	O
2	O
.	O
56	O
–	O
6	O
.	O
72	O
)	O


≥	O
5	O

62	O
/	O
156	O
(	O
39	O
.	O
7	O
)	O

9	O
.	O
29	O

(	O
5	O
.	O
54	O
–	O
15	O
.	O
57	O
)	O

10	O
.	O
63	O

(	O
6	O
.	O
16	O
–	O
18	O
.	O
36	O
)	O

No	O
.	O
of	O
partners	O
in	O
the	O
last	O
6	O
months	O

0	O
-	O
1	O

181	O
/	O
1031	O
(	O
17	O
.	O
6	O
)	O

1	O

-	O




≥	O
2	O

24	O
/	O
62	O
(	O
38	O
.	O
7	O
)	O

2	O
.	O
96	O

(	O
1	O
.	O
73	O
–	O
5	O
.	O
07	O
)	O



Use	O
of	O
contraceptives	O
in	O
the	O
last	O
6	O
months	O

No	O

35	O
/	O
261	O
(	O
13	O
.	O
4	O
)	O

1	O

-	O

1	O

-	O


Yes	O

159	O
/	O
762	O
(	O
20	O
.	O
9	O
)	O

1	O
.	O
70	O

(	O
1	O
.	O
14	O
–	O
2	O
.	O
53	O
)	O

1	O
.	O
67	O

(	O
1	O
.	O
09	O
–	O
2	O
.	O
54	O
)	O

Use	O
of	O
condoms	O
in	O
the	O
last	O
6	O
months	O

Always	O

68	O
/	O
346	O
(	O
19	O
.	O
7	O
)	O

1	O

-	O




Rarely	O

65	O
/	O
307	O
(	O
21	O
.	O
2	O
)	O

1	O
.	O
10	O

(	O
0	O
.	O
75	O
–	O
1	O
.	O
60	O
)	O




Never	O

61	O
/	O
367	O
(	O
16	O
.	O
6	O
)	O

0	O
.	O
81	O

(	O
0	O
.	O
56	O
–	O
1	O
.	O
19	O
)	O



Previous	O
Pap	O
-	O
test	O

No	O

135	O
/	O
671	O
(	O
20	O
.	O
1	O
)	O

1	O

-	O




Yes	O

70	O
/	O
420	O
(	O
16	O
.	O
7	O
)	O

0	O
.	O
79	O

(	O
0	O
.	O
58	O
–	O
1	O
.	O
09	O
)	O



*	O
mean	O
.	O

**	O
The	O
following	O
variables	O
have	O
been	O
included	O
in	O
the	O
multivariate	O
model	O
:	O
marital	O
status	O
,	O
living	O
with	O
,	O
mean	O
age	O
at	O
first	O
sexual	O
intercourse	O
,	O
mean	O
age	O
at	O
first	O
delivery	O
,	O
parity	O
,	O
number	O
of	O
lifetime	O
partners	O
,	O
number	O
of	O
partners	O
in	O
the	O
last	O
6	O
months	O
,	O
use	O
of	O
contraceptives	O
in	O
the	O
last	O
6	O
months	O
.	O

The	O
genotyping	O
was	O
performed	O
on	O
202	O
/	O
205	O
HR	O
-	O
HPV	B-OG
positive	O
samples	O
(	O
three	O
samples	O
were	O
not	O
adequate	O
because	O
material	O
was	O
not	O
sufficient	O
for	O
genotyping	O
)	O
and	O
194	O
(	O
96	O
%)	O
showed	O
positivity	O
at	O
least	O
for	O
one	O
of	O
the	O
18	O
types	O
identifiable	O
by	O
the	O
kit	O
assay	O
used	O
for	O
genotyping	O
.	O

In	O
contrast	O
,	O
eight	O
samples	O
(	O
4	O
%)	O
did	O
not	O
result	O
positive	O
at	O
any	O
of	O
these	O
18	O
types	O
:	O
this	O
proportion	O
is	O
in	O
line	O
with	O
data	O
reported	O
in	O
literature	O
[	O
17	O
,	O
18	O
]	O
and	O
is	O
mainly	O
due	O
to	O
the	O
cross	O
-	O
reactivity	O
of	O
the	O
probe	O
B	O
with	O
low	O
-	O
risk	O
HPV	B-OG
types	O
.	O

Among	O
Hybrid	O
Capture	O
positive	O
women	O
HPV16	B-OG
was	O
the	O
most	O
prevalent	O
type	O
(	O
30	O
.	O
9	O
%),	O
followed	O
by	O
31	O
(	O
19	O
.	O
6	O
%),	O
66	O
(	O
12	O
.	O
9	O
%),	O
51	O
(	O
11	O
.	O
3	O
%),	O
18	O
(	O
8	O
.	O
8	O
%),	O
56	O
(	O
8	O
.	O
8	O
%)	O
and	O
58	O
(	O
8	O
.	O
3	O
%);	O
all	O
the	O
other	O
types	O
were	O
detected	O
at	O
frequencies	O
lower	O
than	O
5	O
.	O
2	O
%	O
(	O
Table	O
3	O
);	O
the	O
cumulative	O
rate	O
of	O
16	O
and	O
18	O
was	O
38	O
.	O
7	O
%.	O

Distribution	O
of	O
HPV	B-OG
genotypes	O
in	O
HR	O
-	O
HC2	O
test	O
positive	O
women	O
and	O
overall	O
population	O

HPV	B-OG
genotypes	O

Number	O
of	O
infections	B-DS

HR	O
-	O
HC2	O
test	O
positive	O
women	O
(	O
N	O
=	O
194	O
),	O
%	O

Overall	O
population	O
*	O
(	O
N	O
=	O
1094	O
),	O
%	O

16	O

60	O

30	O
.	O
9	O

5	O
.	O
5	O

31	O

38	O

19	O
.	O
6	O

3	O
.	O
5	O

66	O
**	O

25	O

12	O
.	O
9	O

2	O
.	O
3	O

51	O

22	O

11	O
.	O
3	O

2	O
.	O
0	O

18	O

17	O

8	O
.	O
8	O

1	O
.	O
6	O

56	O

17	O

8	O
.	O
8	O

1	O
.	O
6	O

58	O

16	O

8	O
.	O
3	O

1	O
.	O
5	O

59	O

10	O

5	O
.	O
2	O

0	O
.	O
9	O

52	O

9	O

4	O
.	O
6	O

0	O
.	O
8	O

39	O

9	O

4	O
.	O
6	O

0	O
.	O
8	O

45	O

8	O

4	O
.	O
1	O

0	O
.	O
7	O

53	O
**	O

7	O

3	O
.	O
6	O

0	O
.	O
6	O

33	O

6	O

3	O
.	O
1	O

0	O
.	O
5	O

68	O

6	O

3	O
.	O
1	O

0	O
.	O
5	O

73	O
**	O

3	O

1	O
.	O
5	O

0	O
.	O
3	O

35	O

2	O

1	O
.	O
0	O

0	O
.	O
2	O

82	O
**	O

1	O

0	O
.	O
5	O

0	O
.	O
1	O

26	O
**	O

0	O

0	O
.	O
0	O

0	O
.	O
0	O

*	O
HPV	B-OG
type	O
-	O
specific	O
prevalence	O
has	O
been	O
extrapolated	O
to	O
overall	O
population	O
although	O
it	O
should	O
be	O
stressed	O
that	O
the	O
genotyping	O
was	O
performed	O
only	O
on	O
HR	O
-	O
HC2	O
positive	O
samples	O
.	O

**	O
The	O
prevalence	O
of	O
HPV	B-OG
26	O
,	O
53	O
,	O
66	O
,	O
73	O
,	O
82	O
is	O
probably	O
underestimated	O
because	O
these	O
HPV	B-OG
types	O
are	O
detected	O
by	O
the	O
“	O
Consensus	O
High	O
Risk	O
HPV	B-OG
genotyping	O
”	O
assay	O
,	O
but	O
they	O
are	O
not	O
targeted	O
by	O
the	O
HR	O
-	O
HC2	O
test	O
.	O

The	O
prevalence	O
of	O
HPV	B-OG
26	O
,	O
53	O
,	O
66	O
,	O
73	O
,	O
82	O
is	O
underestimated	O
because	O
these	O
HPV	B-OG
types	O
are	O
detected	O
by	O
the	O
“	O
Consensus	O
High	O
Risk	O
HPV	B-OG
genotyping	O
”	O
assay	O
,	O
but	O
they	O
are	O
not	O
targeted	O
by	O
HR	O
-	O
HC2	O
test	O
;	O
the	O
detection	O
of	O
HPV	B-OG
26	O
,	O
53	O
,	O
66	O
,	O
73	O
,	O
82	O
is	O
due	O
to	O
an	O
occasional	O
cross	O
-	O
hybridization	O
of	O
HR	O
-	O
HC2	O
method	O
or	O
co	B-DS
-	I-DS
infection	I-DS
with	O
HPV	B-OG
-	O
targeted	O
types	O
,	O
therefore	O
they	O
could	O
more	O
likely	O
appear	O
in	O
multiple	O
than	O
single	O
infections	B-DS
.	O

For	O
this	O
reason	O
we	O
limited	O
the	O
analysis	O
of	O
multiple	O
infections	B-DS
to	O
the	O
13	O
HR	O
-	O
HPV	B-OG
types	O
targeted	O
by	O
HR	O
-	O
HC2	O
test	O
.	O

Out	O
of	O
181	O
women	O
infected	O
by	O
HR	O
-	O
HC2	O
targeted	O
types	O
,	O
37	O
(	O
20	O
.	O
4	O
%)	O
had	O
a	O
multiple	O
infection	B-DS
(	O
36	O
infected	O
by	O
two	O
types	O
and	O
one	O
by	O
three	O
types	O
).	O

No	O
difference	O
in	O
socio	O
-	O
demographic	O
characteristics	O
and	O
sexual	O
and	O
reproductive	O
history	O
was	O
found	O
between	O
women	O
presenting	O
a	O
multiple	O
and	O
single	O
infection	B-DS
.	O

HPV16	B-OG
was	O
the	O
most	O
common	O
genotype	O
detected	O
in	O
multiple	O
infections	B-DS
,	O
followed	O
by	O
HPV31	B-OG
and	O
18	O
.	O

Table	O
4	O
shows	O
the	O
distribution	O
of	O
HPV	B-OG
types	O
in	O
single	O
and	O
multiple	O
infections	B-DS
;	O
the	O
proportion	O
of	O
single	O
and	O
co	B-DS
-	I-DS
infections	I-DS
by	O
genotype	O
is	O
also	O
reported	O
:	O
the	O
proportion	O
of	O
infections	B-DS
occurring	O
in	O
conjunction	O
with	O
other	O
types	O
did	O
not	O
significantly	O
differ	O
by	O
HPV	B-OG
type	O
(	O
Fisher	O
’	O
s	O
exact	O
test	O
:	O
p	O
=	O
0	O
.	O
264	O
).	O

Distribution	O
of	O
HPV	B-OG
genotypes	O
in	O
single	O
/	O
multiple	O
infections	B-DS
and	O
proportion	O
of	O
single	O
/	O
multiple	O
infections	B-DS
by	O
type	O

HPV	B-OG
genotypes	O
*	O

Single	O
infections	B-DS

Multiple	O
infections	B-DS

n	O

%**	O

n	O

%**	O

16	O

43	O

71	O
.	O
7	O

17	O

28	O
.	O
3	O

31	O

21	O

55	O
.	O
3	O

17	O

44	O
.	O
7	O

51	O

16	O

72	O
.	O
7	O

6	O

27	O
.	O
3	O

18	O

7	O

41	O
.	O
2	O

10	O

58	O
.	O
8	O

56	O

12	O

70	O
.	O
6	O

5	O

29	O
.	O
4	O

58	O

11	O

68	O
.	O
7	O

5	O

31	O
.	O
3	O

59	O

6	O

60	O
.	O
0	O

4	O

40	O
.	O
0	O

52	O

5	O

55	O
.	O
6	O

4	O

44	O
.	O
4	O

39	O

6	O

66	O
.	O
7	O

3	O

33	O
.	O
3	O

45	O

7	O

87	O
.	O
5	O

1	O

12	O
.	O
5	O

33	O

3	O

50	O
.	O
0	O

3	O

50	O
.	O
0	O

68	O

6	O

100	O
.	O
0	O

0	O

0	O
.	O
0	O

35	O

1	O

50	O
.	O
0	O

1	O

50	O
.	O
0	O

All	O

144	O

65	O
.	O
5	O

76	O

34	O
.	O
5	O

*	O
All	O
genotypes	O
from	O
single	O
and	O
multiple	O
infections	B-DS
were	O
computed	O
individually	O
.	O

**	O
The	O
denominator	O
is	O
represented	O
by	O
the	O
total	O
number	O
of	O
infections	B-DS
(	O
single	O
plus	O
multiple	O
)	O
by	O
genotype	O
.	O

Determinants	O
of	O
high	O
risk	O
HPV	B-OG
prevalence	O

The	O
univariate	O
analysis	O
of	O
socio	O
-	O
behavioural	O
characteristics	O
and	O
HR	O
-	O
HPV	B-DS
infection	I-DS
is	O
reported	O
in	O
Table	O
2	O
.	O

The	O
risk	O
of	O
HR	O
-	O
HPV	B-DS
infection	I-DS
resulted	O
significantly	O
higher	O
in	O
women	O
who	O
declared	O
a	O
greater	O
number	O
of	O
partners	O
in	O
lifetime	O
(	O
OR	O
=	O
3	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
40	O
-	O
5	O
.	O
94	O
if	O
2	O
–	O
4	O
partners	O
and	O
OR	O
=	O
9	O
.	O
29	O
,	O
95	O
%	O
CI	O
:	O
5	O
.	O
54	O
-	O
15	O
.	O
57	O
if	O
≥	O
5	O
partners	O
)	O
and	O
in	O
the	O
last	O
six	O
months	O
(	O
OR	O
=	O
2	O
.	O
96	O
,	O
95	O
%	O
CI	O
1	O
.	O
73	O
-	O
5	O
.	O
07	O
if	O
≥	O
2	O
partners	O
),	O
and	O
in	O
women	O
who	O
have	O
used	O
any	O
contraceptive	O
method	O
in	O
the	O
last	O
six	O
months	O
(	O
OR	O
=	O
1	O
.	O
70	O
,	O
95	O
%	O
CI	O
1	O
.	O
14	O
-	O
2	O
.	O
53	O
).	O

In	O
contrast	O
,	O
the	O
risk	O
of	O
HR	O
-	O
HPV	B-DS
infection	I-DS
resulted	O
significantly	O
lower	O
in	O
women	O
living	O
with	O
their	O
partner	O
compared	O
to	O
women	O
living	O
with	O
parents	O
/	O
friends	O
/	O
alone	O
(	O
OR	O
=	O
0	O
.	O
53	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
33	O
-	O
0	O
.	O
86	O
),	O
in	O
married	O
women	O
(	O
OR	O
=	O
0	O
.	O
30	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
14	O
-	O
0	O
.	O
63	O
)	O
and	O
women	O
with	O
children	O
(	O
OR	O
=	O
0	O
.	O
43	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
22	O
-	O
0	O
.	O
84	O
).	O

Also	O
a	O
higher	O
age	O
at	O
the	O
first	O
intercourse	O
showed	O
a	O
protective	O
effect	O
(	O
OR	O
=	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
85	O
-	O
0	O
.	O
99	O
).	O

The	O
following	O
variables	O
were	O
included	O
in	O
the	O
multivariate	O
model	O
:	O
marital	O
status	O
,	O
“	O
living	O
with	O
”,	O
age	O
at	O
first	O
sexual	O
intercourse	O
,	O
age	O
at	O
first	O
delivery	O
,	O
parity	O
,	O
number	O
of	O
lifetime	O
partners	O
,	O
number	O
of	O
partners	O
in	O
the	O
last	O
six	O
months	O
,	O
use	O
of	O
contraceptives	O
in	O
the	O
last	O
six	O
months	O
.	O

In	O
the	O
multivariate	O
logistic	O
regression	O
model	O
(	O
Table	O
2	O
),	O
the	O
effect	O
of	O
the	O
number	O
of	O
lifetime	O
sexual	O
partner	O
remained	O
statistically	O
significant	O
(	O
ORadj	O
=	O
4	O
.	O
15	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
56	O
-	O
6	O
.	O
72	O
if	O
2	O
–	O
4	O
partners	O
and	O
ORadj	O
=	O
10	O
.	O
63	O
,	O
95	O
%	O
CI	O
:	O
6	O
.	O
16	O
-	O
18	O
.	O
36	O
if	O
≥	O
5	O
partners	O
).	O

Also	O
,	O
living	O
with	O
the	O
sexual	O
partner	O
and	O
having	O
used	O
any	O
contraceptive	O
in	O
the	O
last	O
six	O
months	O
remained	O
significantly	O
associated	O
with	O
the	O
detection	O
of	O
HR	O
-	O
HPV	B-DS
infection	I-DS
(	O
ORadj	O
=	O
0	O
.	O
56	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
34	O
-	O
0	O
.	O
92	O
and	O
ORadj	O
=	O
1	O
.	O
67	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
2	O
.	O
54	O
respectively	O
).	O

Cytology	O

The	O
pap	O
-	O
test	O
result	O
was	O
available	O
for	O
1	O
,	O
093	O
/	O
1	O
,	O
094	O
cervical	O
smears	O
tested	O
for	O
HR	O
-	O
HC2	O
;	O
5	O
.	O
7	O
%	O
(	O
62	O
/	O
1	O
,	O
093	O
)	O
of	O
samples	O
were	O
inadequate	O
,	O
cytology	O
was	O
normal	O
in	O
83	O
.	O
0	O
%	O
samples	O
(	O
907	O
/	O
1	O
,	O
093	O
)	O
and	O
abnormal	O
in	O
11	O
.	O
3	O
%	O
(	O
124	O
/	O
1	O
,	O
093	O
)	O
samples	O
:	O
62	O
ASCUS	O
/	O
AGUS	O
(	O
atypical	O
squamous	O
/	O
glandular	O
cervical	O
cells	O
of	O
undetermined	O
significance	O
),	O
52	O
LSIL	O
,	O
6	O
ASCH	O
and	O
4	O
HSIL	O
.	O

The	O
proportion	O
of	O
HR	O
-	O
HPV	B-OG
positivity	O
was	O
significantly	O
higher	O
in	O
women	O
with	O
abnormal	O
cytology	O
(	O
65	O
/	O
124	O
,	O
52	O
.	O
4	O
%)	O
than	O
in	O
women	O
with	O
normal	O
cytology	O
(	O
132	O
/	O
907	O
,	O
14	O
.	O
6	O
%)	O
(	O
p	O
<	O
0	O
,	O
001	O
).	O

Among	O
the	O
197	O
HPV	B-OG
-	O
infected	O
women	O
with	O
adequate	O
cytology	O
,	O
65	O
(	O
33	O
.	O
0	O
%)	O
had	O
an	O
abnormal	O
finding	O
.	O

HPV16	B-OG
was	O
the	O
most	O
frequent	O
virus	O
strain	O
in	O
normal	O
cytology	O
,	O
ASCUS	O
/	O
AGUS	O
,	O
LSIL	O
and	O
ASCH	O
,	O
detected	O
in	O
29	O
.	O
3	O
,	O
47	O
.	O
8	O
,	O
24	O
.	O
2	O
and	O
66	O
.	O
7	O
%	O
of	O
the	O
samples	O
respectively	O
.	O

All	O
the	O
four	O
HSIL	O
were	O
HR	O
-	O
HPV	B-OG
positive	O
and	O
four	O
different	O
types	O
were	O
detected	O
respectively	O
(	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
).	O

Discussion	O

We	O
found	O
a	O
prevalence	O
of	O
HR	O
-	O
HPV	B-DS
infections	I-DS
of	O
19	O
%	O
in	O
a	O
sample	O
of	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O
.	O

This	O
percentage	O
is	O
in	O
agreement	O
with	O
an	O
Italian	O
study	O
which	O
used	O
a	O
similar	O
methodology	O
to	O
measure	O
the	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
18	O
–	O
24	O
year	O
-	O
old	O
women	O
from	O
Tuscany	O
Region	O
[	O
11	O
].	O

This	O
value	O
is	O
also	O
included	O
within	O
the	O
range	O
(	O
20	O
-	O
45	O
%)	O
reported	O
in	O
other	O
national	O
or	O
worldwide	O
studies	O
for	O
women	O
younger	O
than	O
25	O
years	O
[	O
12	O
,	O
19	O
-	O
22	O
],	O
although	O
it	O
is	O
difficult	O
to	O
compare	O
results	O
of	O
different	O
studies	O
because	O
of	O
different	O
age	O
groups	O
and	O
different	O
procedures	O
for	O
enrolling	O
participants	O
.	O

Not	O
surprisingly	O
,	O
the	O
rate	O
of	O
infection	B-DS
in	O
this	O
age	O
group	O
was	O
higher	O
than	O
what	O
was	O
found	O
in	O
women	O
aged	O
25	O
–	O
29	O
(	O
14	O
%)	O
in	O
New	O
Technologies	O
for	O
CC	B-DS
screening	O
(	O
NTCC	O
)	O
randomized	O
trials	O
,	O
which	O
studied	O
45	O
,	O
000	O
women	O
aged	O
25	O
–	O
60	O
years	O
of	O
northern	O
and	O
central	O
Italy	O
,	O
participating	O
in	O
CC	B-DS
screening	O
programmes	O
[	O
8	O
,	O
9	O
].	O

This	O
finding	O
reflects	O
a	O
higher	O
probability	O
of	O
acquiring	O
new	O
infections	B-DS
at	O
younger	O
ages	O
,	O
confirming	O
the	O
trend	O
described	O
in	O
the	O
international	O
literature	O
with	O
a	O
peak	O
of	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
younger	O
women	O
and	O
a	O
continuous	O
decline	O
with	O
increasing	O
age	O
[	O
19	O
-	O
22	O
].	O

Cervical	B-DS
cancer	I-DS
incidence	O
is	O
lower	O
in	O
the	O
South	O
than	O
in	O
the	O
North	O
of	O
Italy	O
,	O
therefore	O
a	O
lower	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
the	O
general	O
population	O
was	O
expected	O
in	O
the	O
South	O
.	O

Instead	O
,	O
we	O
did	O
not	O
find	O
any	O
difference	O
in	O
HR	O
-	O
HPV	B-OG
prevalence	O
rates	O
between	O
northern	O
,	O
central	O
and	O
southern	O
regions	O
of	O
Italy	O
,	O
confirming	O
what	O
reported	O
by	O
Agarossi	O
and	O
coll	O
.	O

[	O
22	O
].	O

This	O
finding	O
should	O
encourage	O
the	O
implementation	O
,	O
strengthening	O
and	O
promotion	O
of	O
cervical	B-DS
cancer	I-DS
screening	O
programmes	O
in	O
southern	O
Italy	O
,	O
where	O
coverage	O
and	O
acceptance	O
are	O
still	O
lower	O
than	O
in	O
the	O
rest	O
of	O
the	O
country	O
[	O
23	O
].	O

Genotype	O
HPV16	B-OG
was	O
detected	O
in	O
31	O
%	O
of	O
HR	O
-	O
HC2	O
positive	O
samples	O
,	O
followed	O
by	O
31	O
,	O
66	O
,	O
51	O
and	O
18	O
.	O

This	O
is	O
well	O
consistent	O
with	O
the	O
results	O
of	O
a	O
comprehensive	O
meta	O
-	O
analysis	O
on	O
HPV	B-OG
positive	O
women	O
with	O
normal	O
cytology	O
conducted	O
by	O
de	O
Sanjosé	O
and	O
coll	O
.	O

[	O
24	O
],	O
which	O
reported	O
HPV16	B-OG
,	O
31	O
and	O
18	O
among	O
the	O
five	O
most	O
common	O
types	O
worldwide	O
.	O

In	O
Italy	O
,	O
HPV16	B-OG
resulted	O
to	O
be	O
the	O
genotype	O
most	O
frequently	O
detected	O
in	O
all	O
studies	O
and	O
HPV	B-OG
31	I-OG
was	O
frequently	O
reported	O
as	O
the	O
second	O
most	O
common	O
genotype	O
[	O
11	O
,	O
22	O
,	O
25	O
,	O
26	O
].	O

Regarding	O
the	O
other	O
genotypes	O
a	O
high	O
variability	O
is	O
reported	O
among	O
studies	O
,	O
which	O
could	O
be	O
due	O
to	O
geographical	O
differences	O
,	O
different	O
target	O
populations	O
,	O
different	O
methods	O
for	O
genotyping	O
and	O
random	O
fluctuation	O
for	O
quite	O
rare	O
genotypes	O
[	O
27	O
,	O
28	O
].	O

According	O
to	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
(	O
IARC	O
)	O
classification	O
,	O
HPV16	B-OG
,	O
31	O
,	O
51	O
and	O
18	O
are	O
classified	O
as	O
“	O
carcinogenic	O
to	O
humans	B-OG
”,	O
while	O
HPV	B-OG
66	O
is	O
classified	O
as	O
“	O
possibly	O
carcinogenic	O
”	O
[	O
29	O
].	O

It	O
should	O
be	O
also	O
mentioned	O
that	O
the	O
prevalence	O
of	O
HPV	B-OG
66	O
,	O
as	O
of	O
the	O
other	O
genotypes	O
not	O
targeted	O
by	O
HR	O
-	O
HC2	O
(	O
HPV	B-OG
53	O
,	O
26	O
,	O
73	O
,	O
82	O
),	O
observed	O
in	O
the	O
present	O
study	O
is	O
plausibly	O
underestimated	O
because	O
the	O
detection	O
of	O
these	O
types	O
is	O
only	O
due	O
to	O
an	O
occasional	O
cross	O
-	O
hybridization	O
of	O
the	O
method	O
or	O
co	B-DS
-	I-DS
infection	I-DS
with	O
HPV	B-OG
-	O
targeted	O
types	O
.	O

As	O
expected	O
,	O
we	O
found	O
that	O
women	O
with	O
cervical	O
cytological	O
abnormalities	O
were	O
at	O
significantly	O
increased	O
risk	O
for	O
being	O
infected	O
by	O
HR	O
-	O
HPV	B-OG
types	O
than	O
women	O
with	O
normal	O
cytology	O
(	O
52	O
vs	O
.	O
15	O
%).	O

Current	O
Italian	O
studies	O
involving	O
women	O
with	O
cytological	O
abnormalities	O
(	O
different	O
ages	O
and	O
enrolment	O
criteria	O
)	O
reported	O
HR	O
-	O
HPV	B-OG
prevalence	O
of	O
34	O
-	O
68	O
%,	O
increasing	O
with	O
cytology	O
severity	O
:	O
24	O
-	O
56	O
%	O
in	O
case	O
of	O
diagnosis	O
of	O
ASCUS	O
/	O
AGUS	O
,	O
42	O
-	O
72	O
%	O
in	O
LSIL	O
and	O
73	O
-	O
95	O
%	O
in	O
HSIL	O
[	O
21	O
,	O
22	O
,	O
26	O
,	O
27	O
,	O
30	O
-	O
32	O
].	O

Co	B-DS
-	I-DS
infections	I-DS
of	O
HR	O
-	O
HC2	O
targeted	O
types	O
represented	O
the	O
20	O
%	O
of	O
HPV	B-OG
positive	O
samples	O
.	O

This	O
value	O
is	O
included	O
in	O
the	O
range	O
(	O
15	O
-	O
50	O
%)	O
reported	O
in	O
literature	O
[	O
33	O
];	O
similar	O
percentages	O
of	O
single	O
and	O
multiple	O
HPV	B-DS
infections	I-DS
have	O
been	O
observed	O
in	O
young	O
general	O
populations	O
[	O
34	O
,	O
35	O
].	O

It	O
is	O
still	O
not	O
clear	O
whether	O
co	B-DS
-	I-DS
infection	I-DS
with	O
multiple	O
types	O
increases	O
the	O
risk	O
of	O
progression	O
to	O
cancer	B-DS
[	O
22	O
,	O
36	O
].	O

The	O
multivariate	O
analysis	O
evidenced	O
the	O
role	O
of	O
the	O
number	O
of	O
lifetime	O
sexual	O
partners	O
as	O
determinant	O
of	O
HPV	B-DS
infection	I-DS
,	O
consistently	O
with	O
other	O
studies	O
[	O
11	O
,	O
12	O
,	O
21	O
,	O
37	O
],	O
and	O
strengthens	O
the	O
concept	O
that	O
that	O
the	O
most	O
suitable	O
age	O
for	O
HPV	B-OG
vaccination	O
is	O
the	O
period	O
preceding	O
sexual	O
activity	O
.	O

Living	O
with	O
partner	O
had	O
a	O
protective	O
effect	O
against	O
HR	O
-	O
HPV	B-DS
infection	I-DS
in	O
the	O
multivariate	O
model	O
;	O
consistently	O
with	O
another	O
Italian	O
study	O
[	O
38	O
],	O
being	O
married	O
and	O
having	O
children	O
showed	O
a	O
protective	O
effect	O
in	O
the	O
crude	O
analysis	O
,	O
although	O
not	O
statistically	O
significant	O
in	O
the	O
multivariate	O
analysis	O
.	O

All	O
these	O
variables	O
could	O
be	O
considered	O
markers	O
of	O
a	O
steady	O
relationship	O
,	O
explaining	O
the	O
association	O
with	O
a	O
low	O
HR	O
-	O
HPV	B-OG
prevalence	O
.	O

The	O
use	O
of	O
any	O
contraceptive	O
method	O
in	O
the	O
last	O
six	O
months	O
remained	O
associated	O
to	O
HR	O
-	O
HPV	B-DS
infection	I-DS
in	O
the	O
final	O
model	O
;	O
we	O
could	O
suppose	O
that	O
women	O
who	O
used	O
contraceptives	O
in	O
the	O
last	O
six	O
months	O
could	O
have	O
had	O
a	O
more	O
intense	O
sexual	O
activity	O
,	O
with	O
a	O
higher	O
risk	O
of	O
acquiring	O
HPV	B-OG
,	O
whose	O
prevalence	O
is	O
higher	O
in	O
young	O
ages	O
.	O

If	O
considering	O
only	O
the	O
use	O
of	O
condoms	O
in	O
the	O
last	O
six	O
months	O
,	O
no	O
association	O
was	O
detected	O
between	O
HR	O
-	O
HPV	B-OG
prevalence	O
and	O
this	O
method	O
of	O
contraception	O
;	O
this	O
point	O
is	O
debated	O
and	O
conclusions	O
about	O
the	O
association	O
between	O
condoms	O
’	O
use	O
and	O
HR	O
-	O
HPV	B-OG
prevalence	O
are	O
discordant	O
among	O
authors	O
[	O
11	O
].	O

The	O
major	O
strengths	O
of	O
this	O
study	O
are	O
that	O
the	O
sample	O
was	O
large	O
and	O
it	O
targeted	O
an	O
age	O
group	O
that	O
has	O
not	O
been	O
investigated	O
extensively	O
.	O

Among	O
the	O
limitations	O
,	O
it	O
should	O
be	O
mentioned	O
the	O
fact	O
that	O
our	O
sample	O
may	O
not	O
be	O
entirely	O
representative	O
of	O
Italy	O
’	O
s	O
general	O
population	O
of	O
females	O
aged	O
18	O
–	O
26	O
years	O
because	O
only	O
ten	O
LHUs	O
in	O
six	O
Regions	O
participated	O
,	O
though	O
local	O
probabilistic	O
samples	O
were	O
population	O
-	O
based	O
and	O
both	O
urban	O
and	O
rural	O
LHUs	O
in	O
northern	O
,	O
central	O
and	O
southern	O
Italy	O
were	O
involved	O
.	O

In	O
addition	O
the	O
participation	O
rate	O
was	O
52	O
%,	O
therefore	O
our	O
findings	O
could	O
not	O
be	O
representative	O
of	O
the	O
entire	O
study	O
population	O
;	O
however	O
differences	O
in	O
socio	O
-	O
demographic	O
characteristics	O
between	O
participants	O
and	O
people	O
who	O
declined	O
participation	O
were	O
minimal	O
.	O

The	O
participation	O
rate	O
could	O
be	O
underestimated	O
because	O
we	O
have	O
excluded	O
from	O
the	O
initial	O
sample	O
the	O
154	O
women	O
who	O
spontaneously	O
declared	O
not	O
to	O
be	O
sexually	O
active	O
,	O
but	O
we	O
do	O
not	O
know	O
if	O
other	O
women	O
,	O
who	O
declined	O
participation	O
,	O
were	O
virgin	O
too	O
(	O
we	O
did	O
not	O
collect	O
this	O
information	O
).	O

This	O
age	O
group	O
represents	O
a	O
difficult	O
target	O
for	O
prevention	O
measures	O
,	O
because	O
in	O
Italy	O
young	O
adult	O
women	O
are	O
not	O
accustomed	O
to	O
being	O
targeted	O
by	O
preventive	O
programmes	O
;	O
moreover	O
,	O
enrolled	O
women	O
were	O
offered	O
the	O
participation	O
to	O
a	O
package	O
of	O
activities	O
within	O
the	O
PreGio	O
project	O
,	O
which	O
is	O
more	O
difficult	O
to	O
be	O
accepted	O
than	O
a	O
single	O
cervical	O
smear	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
should	O
be	O
noted	O
that	O
the	O
study	O
personnel	O
had	O
received	O
special	O
training	O
and	O
that	O
a	O
high	O
number	O
of	O
attempts	O
were	O
made	O
to	O
contact	O
non	O
-	O
respondents	O
.	O

Two	O
other	O
studies	O
[	O
11	O
,	O
12	O
],	O
which	O
detected	O
HPV	B-OG
prevalence	O
of	O
a	O
sample	O
of	O
Italian	O
women	O
aged	O
18	O
–	O
24	O
years	O
randomly	O
selected	O
from	O
population	O
registries	O
,	O
got	O
a	O
lower	O
participation	O
rate	O
(	O
15	O
-	O
22	O
%).	O

In	O
these	O
two	O
studies	O
letters	O
of	O
invitation	O
were	O
mailed	O
to	O
sampled	O
women	O
and	O
a	O
reminder	O
was	O
sent	O
in	O
case	O
of	O
no	O
response	O
,	O
whereas	O
we	O
planned	O
three	O
phone	O
calls	O
and	O
two	O
home	O
visits	O
for	O
non	O
respondents	O
.	O

As	O
already	O
mentioned	O
,	O
another	O
limitation	O
is	O
that	O
the	O
prevalence	O
of	O
HPV	B-OG
26	O
,	O
53	O
,	O
66	O
,	O
73	O
and	O
82	O
could	O
be	O
heavily	O
underestimated	O
because	O
they	O
are	O
not	O
targeted	O
by	O
HR	O
-	O
HC2	O
test	O
.	O

In	O
fact	O
HPV	B-OG
73	O
and	O
82	O
were	O
observed	O
only	O
in	O
co	B-DS
-	I-DS
infection	I-DS
with	O
other	O
HR	O
-	O
HPV	B-OG
types	O
,	O
suggesting	O
that	O
they	O
could	O
have	O
been	O
found	O
only	O
because	O
coexisted	O
with	O
HPV	B-OG
types	O
detected	O
by	O
HR	O
-	O
HC2	O
probes	O
B	O
(	O
for	O
this	O
reason	O
we	O
excluded	O
HR	O
-	O
HC2	O
not	O
targeted	O
types	O
from	O
the	O
analysis	O
of	O
co	B-DS
-	I-DS
infections	I-DS
).	O

Conclusion	O

We	O
measured	O
the	O
genital	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
Italian	O
women	O
aged	O
18	O
–	O
26	O
years	O
before	O
the	O
introduction	O
of	O
HPV	B-OG
vaccination	O
across	O
all	O
the	O
areas	O
of	O
Italy	O
;	O
we	O
found	O
a	O
prevalence	O
of	O
19	O
%,	O
higher	O
than	O
what	O
detected	O
for	O
older	O
women	O
[	O
19	O
-	O
22	O
].	O

The	O
use	O
of	O
the	O
same	O
molecular	O
method	O
and	O
laboratory	O
network	O
of	O
the	O
NTCC	O
studies	O
[	O
8	O
,	O
9	O
],	O
targeting	O
women	O
aged	O
25	O
–	O
60	O
years	O
,	O
allowed	O
us	O
to	O
depict	O
a	O
comprehensive	O
picture	O
of	O
HR	O
-	O
HPV	B-OG
prevalence	O
in	O
Italy	O
from	O
18	O
to	O
60	O
years	O
of	O
age	O
,	O
observing	O
in	O
young	O
adult	O
women	O
a	O
peak	O
of	O
prevalence	O
,	O
which	O
drops	O
with	O
increasing	O
age	O
.	O

The	O
findings	O
support	O
the	O
choice	O
of	O
electing	O
girls	O
before	O
the	O
sexual	O
debut	O
as	O
the	O
primary	O
target	O
of	O
HPV	B-OG
vaccination	O
.	O

The	O
HPV	B-OG
type	O
distribution	O
found	O
in	O
this	O
study	O
may	O
represent	O
a	O
baseline	O
picture	O
;	O
an	O
accurate	O
post	O
-	O
vaccine	O
surveillance	O
is	O
,	O
in	O
fact	O
,	O
necessary	O
to	O
early	O
detect	O
a	O
possible	O
genotype	O
replacement	O
.	O

The	O
high	O
prevalence	O
of	O
viral	O
types	O
other	O
than	O
vaccine	O
-	O
HPV	B-OG
types	O
supports	O
the	O
necessity	O
to	O
guarantee	O
the	O
progression	O
of	O
CC	B-DS
screening	O
programmes	O
in	O
vaccinated	O
women	O
.	O

Studies	O
linking	O
screening	O
programmes	O
with	O
vaccine	O
immunization	O
registries	O
should	O
be	O
performed	O
to	O
evaluate	O
the	O
HPV	B-OG
vaccine	O
effectiveness	O
on	O
vaccine	O
-	O
related	O
and	O
not	O
-	O
vaccine	O
related	O
types	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O

CG	O
coordinated	O
and	O
monitored	O
the	O
project	O
activities	O
,	O
analysed	O
the	O
data	O
,	O
interpreted	O
the	O
results	O
,	O
drafted	O
and	O
edited	O
the	O
manuscript	O
.	O

SDo	O
designed	O
the	O
study	O
,	O
coordinated	O
and	O
monitored	O
the	O
project	O
activities	O
,	O
interpreted	O
the	O
results	O
and	O
revised	O
the	O
manuscript	O
.	O

FC	O
and	O
GR	O
participated	O
in	O
the	O
study	O
design	O
,	O
carried	O
out	O
the	O
immunoassays	O
,	O
coordinated	O
the	O
activities	O
of	O
laboratories	O
and	O
revised	O
the	O
manuscript	O
.	O

SS	O
designed	O
the	O
study	O
,	O
interpreted	O
the	O
results	O
and	O
revised	O
the	O
manuscript	O
.	O

SDe	O
coordinated	O
and	O
monitored	O
the	O
project	O
activities	O
and	O
revised	O
the	O
manuscript	O
.	O

MLCdA	O
designed	O
the	O
study	O
,	O
coordinated	O
and	O
monitored	O
the	O
project	O
activities	O
in	O
the	O
first	O
phase	O
of	O
the	O
project	O
and	O
revised	O
the	O
manuscript	O
.	O

AB	O
analysed	O
the	O
data	O
and	O
revised	O
the	O
manuscript	O
.	O

MPA	O
,	O
SB	O
,	O
NC	O
,	O
DF	O
,	O
AL	O
,	O
MCM	O
,	O
RN	O
,	O
EB	O
participated	O
in	O
the	O
study	O
design	O
and	O
coordinated	O
the	O
activities	O
in	O
their	O
local	O
health	O
units	O
.	O

EB	O
,	O
AG	O
,	O
VM	O
,	O
PP	O
carried	O
out	O
the	O
immunoassays	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2334	O
/	O
13	O
/	O
74	O
/	O
prepub	O

